Collegium Pharmaceutical (COLL) has just posted Q1 2026 revenue of US$193.5 million and basic EPS of US$0.45, setting the stage against a trailing twelve month EPS of US$2.36. The company has seen revenue move from US$177.8 million and EPS of US$0.08 in Q1 2025 to US$193.5 million and EPS of US$0.45 in Q1 2026, with trailing twelve month net income of US$74.9 million, so investors are now weighing how this earnings profile and a 9.4% net margin shape the risk and reward ahead.

See our full analysis for Collegium Pharmaceutical.

With the headline numbers on the table, the next step is to see how this earnings story lines up with the most common narratives around Collegium and where the recent results may support or challenge those views.

70.8% earnings growth outpacing 4.3% revenue rise

• Over the last 12 months, revenue increased 4.3% while earnings grew 70.8% and net margin sat at 9.4% compared with 6.6% the prior year, showing a much stronger move in profitability than in sales.
• What stands out for a bullish view is how earnings growth outpaced revenue, which lines up with the idea of a focused pain and ADHD franchise yet also raises questions:
  • Trailing twelve month net income was US$74.9 million on US$796.3 million of revenue, which supports the argument that the commercial portfolio is producing solid profits.
  • At the same time, the 4.3% revenue growth rate is described as below the wider US market, so anyone leaning bullish has to be comfortable that earnings momentum is not purely reliant on faster top line expansion.

Margin progress alongside a US$30.2 million one off loss

• Net margin moved from 6.6% to 9.4% over the last 12 months while the same period still contained a US$30.2 million one off loss, showing cleaner profitability and a sizeable non recurring hit in the same window.
• Bears often worry about quality of earnings in specialty pharma and this combination of margin improvement and a large one off charge creates a mixed picture:
  • The 70.8% earnings growth rate over the year suggests operations added more profit, yet that figure is influenced by the one off loss sitting in the trailing period, which can make growth look stronger than it would without that item.
  • With a high level of debt also flagged in the data, skeptics can fairly argue that both leverage and non recurring charges are important to track when judging how durable that 9.4% margin really is.

P/E of 17x against DCF fair value of US$302.17

• The stock trades on a trailing P/E of 17x at a share price of about US$39.32, a touch above the US Pharmaceuticals average of 16.7x but well below the 50.7x peer average, while a DCF fair value of US$302.17 and an analyst target of US$54.33 both sit above the current price.
• For readers weighing a bullish angle, the gap between price, analyst target and DCF estimate is hard to ignore and ties directly back to the recent earnings run:
  • Analysts in the dataset imply about 38.2% upside from US$39.32 to US$54.33, which lines up with the idea that the current 17x P/E does not fully reflect the 70.8% earnings growth and 9.4% margin recorded over the last year.
  • At the same time, the P/E being close to the industry average suggests the market is already treating Collegium as a typical pharmaceuticals stock, so any investor leaning bullish needs to decide whether the stronger recent profit profile and the DCF fair value of US$302.17 justify treating it differently.

If you want to see how other investors are connecting these valuation signals to the longer term story, it is worth reading through the latest community views on the stock Curious how numbers become stories that shape markets? Explore Community Narratives.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Collegium Pharmaceutical's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

Seeing both risks and rewards in the story so far? Take a closer look at the full data set, and move quickly to shape your own conclusion by weighing the 3 key rewards and 2 important warning signs.

See What Else Is Out There

Collegium's 4.3% revenue growth, reliance on one off adjustments, and a high level of debt show that earnings quality and balance sheet strength are key questions.

If you want more resilient ideas with cleaner finances, use the solid balance sheet and fundamentals stocks screener (44 results) to quickly spot companies where the balance sheet does more of the heavy lifting.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.